Myasthenia gravis patients receiving intravenous immunoglobulin (IVIg) for maintenance therapy will be switched over to subcutaneous immunoglobulin (SCIg) for a 3 month period of time.
Myasthenia gravis patients receiving intravenous immunoglobulin (IVIg) for maintenance therapy will be switched over to subcutaneous immunoglobulin (SCIg) for a 3 month period of time.
To assess safety and efficacy of SCIg in myasthenia gravis.
As under requirements
MG patients with either AChR or MuSK antibodies, stable on IVIg therapy for three cycles prior to entry
None
Nicholas J. Silvestri, Gil I. Wolfe
Name: Connie Brand
Phone: 716-859-7620
Email: conniebr@buffalo.edu